# South America Protein Therapeutics Market

> South America Protein Therapeutics Market Research Report: Size, Share, Trend Analysis By Types (Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon), By Applications (Cancer, Metabolic Disorders, Immunologic Disorders, Hematological Disorders), By End Users (Hospitals and Clinics, Specialty Centers) and By Regional (Brazil, Mexico, Argentina, Rest of South America) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.92%
- **2024:** $ 22.26 Billion
- **2025:** $ 23.8 Billion
- **2035:** $ 46.47 Billion
- **Key Players:** Amgen (US), Genentech (US), AbbVie (US), Bristol-Myers Squibb (US), Roche (CH), Sanofi (FR), Johnson & Johnson (US), Merck & Co. (US), Eli Lilly and Company (US)

**Report ID:** MRFR/Pharma/50035-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** February 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/south-america-protein-therapeutics-market-51793

---

## Market Summary

## **South America Protein Therapeutics Market Overview**

As per MRFR analysis, the South America Protein Therapeutics Market Size was estimated at 20.82 (USD Billion) in 2023. The South America Protein Therapeutics Market Industry is expected to grow from 22.26 (USD Billion) in 2024 to 52.94 (USD Billion) by 2035. The South America Protein Therapeutics Market CAGR (growth rate) is expected to be around 8.194% during the forecast period (2025 - 2035).

## **Key South America Protein Therapeutics Market Trends Highlighted**

The South America Protein Therapeutics Market is currently experiencing notable trends driven by an increase in healthcare investments and a growing focus on biotechnology. Countries like Brazil and Argentina have intensified their efforts in the biopharmaceutical sector, which is propelled by supportive government policies aimed at fostering research and development. The rise in chronic diseases has also fueled demand for targeted protein therapeutics, encouraging pharma companies to invest in innovative treatments. The ongoing collaborations between universities and biotech firms in the region are expected to bolster product development and regulatory approvals, offering a promising landscape for market growth.

Local companies have the opportunity to create niche protein therapeutic products that are specifically designed to address the health challenges and demographics of their region, as a result of the ongoing transition to personalised medicine. The adoption of biosimilars in South America is on the rise, as they have the potential to reduce treatment costs while maintaining efficacy. Market participants can leverage this trend by optimising their supply chains and enhancing patient access to therapies as patient awareness of the advantages of biologics increases.

In recent years, there has been a significant emphasis on sustainability in the production of protein therapeutics. In order to comply with global sustainability objectives, organisations are investigating environmentally friendly packaging and more sustainable production methods. Furthermore, the influence of digital health technologies is transforming the way patients interact with therapeutics, resulting in advancements in treatment adherence and monitoring. In general, the South American Protein Therapeutics Market is well-positioned for expansion as a result of these emerging opportunities and evolving trends.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **South America Protein Therapeutics Market Drivers**

### **Increasing Prevalence of Chronic Diseases**

The South America Protein Therapeutics Market Industry is experiencing significant growth due to the rising prevalence of chronic diseases, including cancer, diabetes, and autoimmune disorders. According to the Pan American Health Organization (PAHO), cancer incidences in South America have increased by approximately 20% over the last decade, contributing to a growing demand for effective protein therapeutics. As major pharmaceutical companies like Roche and Novartis expand their operations in the region, they are creating innovative protein-based therapies specifically tailored to address the unique healthcare challenges faced by South American populations.

This shift towards personalized medicine and biologics indicates a strong potential for the South America Protein Therapeutics Market to thrive, as these therapies are expected to gain prominence in treating chronic conditions, ultimately improving patient outcomes.

### **Government Initiatives Supporting Biotechnology**

The South American government has rolled out several initiatives to promote biotechnology and pharmaceutical research, thereby driving growth in the South America Protein Therapeutics Market Industry. Brazil's Ministry of Science, Technology, Innovations and Communications has launched multiple funds to support Research and Development (R&D) in biopharmaceuticals, allocating over USD 100 million for biotechnology projects in the last two years.

Such government backing not only enhances the capacity for innovation in protein therapeutics but also fosters collaborations between public research institutions and private companies, like Biolab Sanus and Eurofarma, which are paving the way for new protein-based therapies tailored to local needs.

### **Rising Investment in Biopharmaceutical Sector**

In recent years, South America has seen an upsurge in foreign and domestic investments aimed at boosting the biopharmaceutical sector. The region's investment landscape has attracted significant attention, with venture capital in the biotech industry experiencing a growth of roughly 150% since 2019, according to the Argentine Association of Bioinformatics and Biotechnology. Established companies like Amgen and Pfizer are increasingly investing in local partnerships and facilities, focusing on the development of novel protein therapeutics that can cater to the South American market.

This surge in investment is expected to accelerate the growth of the South America Protein Therapeutics Market, enhancing the accessibility and affordability of advanced therapies within the region.

## **South America Protein Therapeutics Market Segment Insights**

### **Protein Therapeutics Market Type Insights**

The South America Protein Therapeutics Market is increasingly diversifying into various types, with several key segments demonstrating considerable importance within the industry. Among these, Monoclonal Antibodies stand out due to their predominant role in treating diseases such as cancer and autoimmune disorders, making them particularly significant. Their ability to target specific antigens has resulted in a growing demand across multiple therapeutic areas, thereby driving market growth in South America. Insulin plays a crucial role in managing diabetes, a condition that is rising in prevalence across South America, subsequently increasing the focus on insulin therapies.

This segment is vital as it addresses not only the medical needs of patients but also broader public health challenges.

Additionally, Fusion Proteins represent a novel approach to treatment, often combining the beneficial effects of different proteins into a single therapeutic option, thus revolutionizing how diseases are managed. Erythropoietin, essential for stimulating red blood cell production, remains important for addressing anemia, which is frequently associated with chronic diseases in the region. Furthermore, Interferon, with its antiviral and immune-modulating properties, continues to be critical in treating multiple sclerosis and hepatitis, underscoring its role in enhancing overall patient health outcomes.

Overall, the segmentation of the South America Protein Therapeutics Market into these types not only reflects the diverse therapeutic needs of the population but also highlights opportunities for future advancements in protein-based treatments, driven by ongoing research and a growing understanding of protein therapeutics.

The market is influenced by factors such as rising incidences of chronic diseases, increased healthcare expenditure, and favorable government initiatives aimed at improving access to advanced therapeutics, ensuring that this market continues to evolve and expand within the region. Overall, each of these segments is positioned to contribute uniquely to the healthcare landscape in South America, addressing various medical needs while also fostering innovation and development in protein-based therapies.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Protein Therapeutics Market Application Insights**

The South America Protein Therapeutics Market, specifically within the Application segment, is experiencing notable growth as it addresses critical health conditions impacting the region. Cancer therapies represent a significant portion of this market, driven by the increasing prevalence of various cancer types, which has led to an upsurge in Research and Development efforts to create innovative treatments. Metabolic Disorders are also a key area of focus due to the rising incidence of diseases such as diabetes and obesity, which spur the demand for therapeutic solutions that can manage these conditions effectively.

Immunologic Disorders, including autoimmune diseases, necessitate advanced protein therapeutics to modulate the immune response, highlighting the importance of this segment in improving patient outcomes. Additionally, Hematological Disorders present a unique challenge, with a need for protein therapeutics that address various blood-related conditions. The collective insights into these applications within the South America Protein Therapeutics Market underline the industry's commitment to enhancing healthcare through targeted therapies that cater to diverse patient needs and conditions across the region. Furthermore, expanding healthcare access and evolving treatment paradigms are expected to propel advancements in these critical therapeutic areas.

### **Protein Therapeutics Market End User Insights**

The South America Protein Therapeutics Market, characterized by its diverse end user landscape, notably includes Hospitals and Clinics alongside Specialty Centers. Hospitals and Clinics, which predominantly serve as primary healthcare providers, play a crucial role in delivering protein therapeutics, which have become vital for treating various chronic and acute conditions. These facilities are equipped to handle patient management, administration, and monitoring of protein therapeutics, ensuring optimal patient care and outcomes. Specialty Centers, on the other hand, focus on specific therapeutic areas, offering advanced treatment options and expertise in the administration of these therapies.

The growing prevalence of chronic diseases in South America drives the demand within these segments, aligning with governmental health initiatives aimed at improving healthcare access and affordability. As the healthcare industry continues to evolve with advances in biotechnology, the end user segments are likely to adapt and expand, fostering a landscape that provides diverse treatment options and improved health outcomes for patients across the region. The interplay of these segments represents a significant portion of the market's overall growth trajectory.

### **Protein Therapeutics Market Regional Insights**

The South America Protein Therapeutics Market showcases a dynamic landscape characterized by significant growth and diverse regional contributions. Brazil emerges as a leader, bolstered by a robust pharmaceutical infrastructure and increasing investment in biotechnology, making it a focal point for innovation and production in the market. Mexico follows closely, leveraging its geographical advantages for manufacturing and distribution, thus attracting investment in Research and Development initiatives. Argentina contributes to the market through strong collaborations in the life sciences sector, aimed at expanding access to biologics.

Meanwhile, the Rest of South America also plays a crucial role, with various nations strengthening their healthcare frameworks and fostering public-private partnerships to enhance biotechnology capabilities. Overall, the South America Protein Therapeutics Market segmentation reflects a blend of established and emerging markets, where demographic trends, healthcare demands, and increasing prevalence of diseases drive the need for protein therapeutics, creating opportunities for growth and innovation across the region.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **South America Protein Therapeutics Market Key Players and Competitive Insights**

The South America Protein Therapeutics Market has been experiencing robust growth over the past few years, driven by increased investments in biotechnology and pharmaceuticals, along with rising healthcare demands in the region. As the market evolves, several key players are competing heavily to solidify their presence and expand their offerings in protein-based therapies. These firms leverage advanced technologies and research capabilities to develop innovative therapeutic solutions targeting various diseases, including cancer, autoimmune disorders, and chronic diseases that are prevalent in South America.

The competitive landscape is characterized by strategic collaborations, mergers and acquisitions, and the pursuit of regional partnerships to enhance market access and gain a competitive edge.

Johnson & Johnson has established a strong foothold in the South America Protein Therapeutics Market. The company's commitment to research and development has positioned it as a leading innovator in protein therapeutics. Johnson & Johnson’s diverse portfolio in South America focuses on biologics, with significant strengths in its established brands and a proactive approach towards addressing local healthcare needs. Their robust distribution network and strategic partnerships further enhance their market presence, allowing for efficient delivery of product offerings.

Additionally, Johnson & Johnson's dedication to sustainability and corporate social responsibility has contributed positively to its brand image, thereby strengthening customer loyalty and trust within the region.

Merck has also emerged as a formidable player in the South America Protein Therapeutics Market, showcasing a comprehensive range of biopharmaceutical products. The company's key services include the development of therapies targeting severe and chronic conditions, leveraging its state-of-the-art research capabilities to deliver cutting-edge solutions. Merck's presence in South America is supported by its aggressive expansion strategy, which includes establishing local partnerships and collaborations to enhance its market reach. The company has made strategic mergers and acquisitions that bolster its portfolio and improve its operational efficiency in the region.

By focusing on innovative products tailored to the specific health challenges of South American populations, Merck has effectively cemented its position as a leading provider of protein therapeutics, while generating a competitive advantage through its ongoing commitment to science and healthcare solutions.

## **Key Companies in the South America Protein Therapeutics Market Include**

- [**Johnson & Johnson**](https://www.careers.jnj.com/pt/empregos/2506235641w/technical-product-owner-protein-therapeutics-development/)
- Merck
- Novartis
- Eli Lilly
- AbbVie
- Takeda
- Sanofi
- Roche
- Amgen
- BristolMyers Squibb
- Pfizer
- Biogen
- AstraZeneca
- Regeneron Pharmaceuticals
- Gilead Sciences

## **South America Protein Therapeutics Market Industry Developments**

The South America Protein Therapeutics Market is experiencing significant developments, particularly with leading companies such as Johnson and Johnson, Merck, Novartis, and Pfizer actively pursuing advancements in biologic therapies. Notably, in March 2023, Novartis announced a strategic partnership with a local biotech firm in Brazil aimed at accelerating the development of novel protein therapeutics targeting chronic diseases prevalent in the region. Additionally, Johnson and Johnson reinforced its commitment to the South American market by expanding its research facilities in Argentina, enhancing its capabilities in protein-based therapies.

In terms of market growth, Eli Lilly has reported impressive increases in its revenue from protein therapeutics, driven by strong demand for its diabetes treatments in Brazil and Argentina. The market valuation for protein therapeutics in South America is projected to reach approximately USD 15 billion by 2025, buoyed by an increase in healthcare spending and a growing prevalence of chronic diseases.

Furthermore, significant regulatory updates have been made in the region, streamlining approval processes for new protein-based therapies to enhance patient access and market entry for innovative treatments, reflecting a maturing landscape for biopharmaceuticals in South America over the past 2-3 years.

## **South America Protein Therapeutics Market Segmentation Insights**

### **Protein Therapeutics Market Type Outlook**

- Monoclonal Antibodies
- Insulin
- Fusion Protein
- Erythropoietin
- Interferon

### **Protein Therapeutics Market Application Outlook**

- Cancer
- Metabolic Disorders
- Immunologic Disorders
- Hematological Disorders

### **Protein Therapeutics Market End User Outlook**

- Hospitals and Clinics
- Specialty Centers

### **Protein Therapeutics Market Regional Outlook**

- Brazil
- Mexico
- Argentina
- Rest of South America

## Market Drivers

### Rising Demand for Biosimilars

The demand for biosimilars is on the rise in South America, driven by the need for affordable alternatives to expensive biologic therapies. As patents for several blockbuster biologics expire, the protein therapeutics market is witnessing an influx of biosimilar products. These alternatives offer similar efficacy and safety profiles at a reduced cost, making them accessible to a broader patient population. Market analysis suggests that the biosimilars segment could capture approximately 30% of the total protein therapeutics market by 2027. This shift not only enhances treatment accessibility but also stimulates competition among manufacturers, potentially leading to further innovations in the protein therapeutics sector. The growing acceptance of biosimilars among healthcare providers and patients is likely to bolster the overall market growth.

### Increased Focus on Preventive Healthcare

There is a growing emphasis on preventive healthcare in South America, which is influencing the protein therapeutics market. As healthcare systems shift towards preventive measures, there is an increasing recognition of the role of protein therapeutics in disease prevention and management. This trend is reflected in the rising adoption of therapies that target early-stage diseases and promote overall health. The protein therapeutics market is likely to benefit from this focus, as innovative treatments that enhance immune response and prevent disease progression gain traction. Projections indicate that the preventive healthcare segment could grow at a CAGR of around 9% over the next few years. This shift towards prevention not only improves patient outcomes but also reduces the long-term burden on healthcare systems, thereby driving demand for protein therapeutics.

### Increasing Prevalence of Chronic Diseases

The rising incidence of chronic diseases in South America is a pivotal driver for the protein therapeutics market. Conditions such as diabetes, cancer, and autoimmune disorders are becoming more prevalent, necessitating innovative treatment options. According to recent health statistics, chronic diseases account for approximately 60% of all deaths in the region. This alarming trend propels the demand for protein therapeutics, which offer targeted and effective treatment solutions. As healthcare systems strive to manage these diseases, the protein therapeutics market is likely to experience substantial growth, with projections indicating a compound annual growth rate (CAGR) of around 8% over the next five years. The increasing burden of chronic diseases underscores the urgent need for advanced therapeutic options, thereby driving investments and research in the protein therapeutics sector.

### Advancements in Biomanufacturing Technologies

Technological advancements in biomanufacturing are significantly influencing the protein therapeutics market in South America. Innovations such as continuous manufacturing and improved cell culture techniques enhance the efficiency and scalability of protein production. These advancements not only reduce production costs but also improve the quality and consistency of therapeutic proteins. The protein therapeutics market is witnessing a shift towards more sustainable and cost-effective manufacturing processes, which could potentially lower the price of therapies for patients. As a result, the market is expected to expand, with estimates suggesting a growth rate of approximately 10% annually. The integration of cutting-edge biomanufacturing technologies is likely to facilitate the development of novel protein therapeutics, thereby addressing unmet medical needs in the region.

### Growing Investment in Research and Development

Investment in research and development (R&D) within South America is a crucial driver for the protein therapeutics market. Governments and private entities are increasingly allocating funds to support biopharmaceutical research, aiming to foster innovation and enhance healthcare outcomes. In recent years, R&D expenditure in the biopharmaceutical sector has seen a notable increase, with estimates indicating a growth of over 15% annually. This influx of funding is likely to accelerate the discovery and development of new protein therapeutics, addressing various health challenges faced by the population. The protein therapeutics market stands to benefit from this trend, as enhanced R&D efforts could lead to breakthroughs in treatment options, ultimately improving patient care and outcomes across the region.

## Future Outlook

The [Protein Therapeutics Market](https://www.marketresearchfuture.com/reports/protein-therapeutics-market-10142) is projected to grow at a 6.92% CAGR from 2025 to 2035, driven by advancements in biotechnology, increasing chronic diseases, and rising healthcare expenditures.

**New opportunities:**

- Development of biosimilars to enhance market access and affordability.
- Investment in personalized medicine to cater to specific patient needs.
- Expansion of distribution networks to improve product availability in remote areas.

By 2035, the protein therapeutics market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Type: Monoclonal Antibodies (Largest) vs. Vaccines (Fastest-Growing)

In the protein therapeutics market, monoclonal antibodies hold the largest market share, reflecting their crucial role in treating various diseases, particularly in oncology and autoimmune disorders. Recombinant proteins and hormones follow, showing significant contributions, while vaccines are capturing attention for their potential in addressing infectious diseases and public health emergencies. Currently, the growth trends highlight the increasing investment in biopharmaceutical research and development, with monoclonal antibodies expected to continue leading due to their high efficacy and specificity. However, vaccines are poised for rapid expansion, driven by global health initiatives and an increased demand for preventive therapies. This dynamic landscape illustrates a competitive and evolving market.

Monoclonal Antibodies (Dominant) vs. Vaccines (Emerging)

Monoclonal antibodies are characterized by their ability to target specific antigens, making them effective in treating complex diseases. Their extensive range of applications and proven effectiveness in clinical settings have positioned them as the dominant force in the market. Conversely, vaccines are emerging as vital tools in disease prevention, supported by advancements in technology and a growing focus on immunization programs. The demand for innovative vaccine solutions, especially in response to recent global health challenges, is driving their rapid growth. Both segments reflect the shift towards precision medicine and public health priorities, highlighting their significant roles in therapeutic strategies.

### By Application: Oncology (Largest) vs. Autoimmune Diseases (Fastest-Growing)

In the South America protein therapeutics market, the application segment is primarily dominated by oncology, which captures the largest share as a result of the increasing incidence of [cancer](https://www.marketresearchfuture.com/reports/liver-cancer-market-26244) and the rising adoption of innovative therapies. Autoimmune diseases follow closely, experiencing a notable share driven by a growing awareness among the population and advancements in treatment protocols that cater to various autoimmune conditions. The growth trends in this segment are expected to be promising, especially for autoimmune diseases, which is emerging as the fastest-growing area due to an increase in diagnostic capabilities and a heightened focus on individualized medicine. Factors such as the rising prevalence of chronic diseases, escalating healthcare spending, and a growing emphasis on research and development in these therapeutic areas are fueling this growth trajectory.

Oncology: Dominant vs. Autoimmune Diseases: Emerging

Oncology remains a dominant application in the protein therapeutics market, characterized by a vast array of treatments aimed at various types of cancers. This segment benefits from continuous innovations, including monoclonal antibodies and targeted therapies, which enhance treatment efficacy and patient outcomes. On the other hand, autoimmune diseases are emerging rapidly, appealing to both patients and healthcare providers. This segment has seen a surge in drug development, supported by increased investments and research efforts to address complex conditions such as rheumatoid arthritis, lupus, and multiple sclerosis. The shift towards personalized medicine and improved diagnostics technology is expected to propel the growth of this segment significantly in the coming years.

### By End Use: Pharmaceutical Companies (Largest) vs. Research Laboratories (Fastest-Growing)

In the South America protein therapeutics market, the Hospital segment holds a significant share, providing critical healthcare services and driving the demand for protein therapeutics. However, Pharmaceutical Companies lead the market, benefiting from robust drug development pipelines and advanced production capabilities. Research Laboratories, while smaller, are quickly gaining traction as they innovate and explore novel therapeutic applications. Growth trends in this segment are influenced by increasing healthcare investments and the rising prevalence of chronic diseases that necessitate sophisticated treatment options. Additionally, regulatory advancements facilitate faster approvals for new therapies, with pharmaceutical companies expanding their research capacities. Research laboratories are becoming increasingly vital as they contribute to translational research, bridging gaps between laboratory discoveries and clinical applications, thus driving their rapid growth.

Hospital (Dominant) vs. Research Laboratories (Emerging)

The Hospital segment is a dominant force in the protein therapeutics landscape, providing essential services and administering a vast array of protein-based therapies. This segment is characterized by well-established infrastructure, comprehensive healthcare networks, and extensive patient access. Hospitals are increasingly adopting innovative therapeutics to enhance treatment outcomes, supported by collaborations with pharmaceutical companies for targeted therapies. Conversely, Research Laboratories are emerging as key players, focusing on cutting-edge research and development. They drive innovation in protein therapeutics, exploring diverse applications ranging from oncology to rare diseases. With increased funding and collaboration with academic institutions, research laboratories are becoming crucial in advancing the pipeline of protein therapeutics, positioning themselves well within the market.

### By Mode of Administration: Intravenous (Largest) vs. Subcutaneous (Fastest-Growing)

In the protein therapeutics market, the mode of administration plays a pivotal role in determining patient compliance and overall treatment efficacy. Currently, intravenous administration dominates the segment due to its rapid absorption and immediate therapeutic effects. A substantial share of the market is associated with intravenous therapies, making it a preferred choice among healthcare providers in South America. Emerging trends indicate a shift toward subcutaneous administration as it offers more convenience and flexibility for patients. This mode is gaining traction quickly, especially for self-administration by patients, thus making it the fastest-growing segment of the market. The increasing focus on personalized medicine and home-based therapies is further propelling this growth, aiding in better patient adherence and outcomes.

Mode of Administration: Intravenous (Dominant) vs. Subcutaneous (Emerging)

Intravenous administration remains the dominant mode of delivering protein therapeutics in the region due to its ability to provide immediate relief and effective drug delivery systems. It is commonly used for administering biologics and complex proteins that require controlled environments to maintain efficacy. On the other hand, subcutaneous administration is emerging as a popular alternative, especially for chronic conditions where patients benefit from self-injection, leading to increased patient autonomy. This method suits therapies that require lower doses and offers ease of use, thus expanding its adoption among patients and healthcare providers alike.

## Regional Market Share Analysis

### Brazil : Strong Growth Driven by Innovation

Brazil holds a dominant market share of 10.5% in the South American protein therapeutics sector, valued at approximately $2.5 billion. Key growth drivers include increasing healthcare expenditure, a rising prevalence of chronic diseases, and government initiatives promoting biotechnology. Regulatory policies are becoming more favorable, with ANVISA streamlining approval processes for new therapeutics. Infrastructure improvements in healthcare facilities are also enhancing access to these treatments.

### Mexico : Growing Demand and Investment Opportunities

With a market share of 4.5%, Mexico's protein therapeutics market is valued at around $1 billion. The growth is fueled by increasing investments in healthcare infrastructure and a rising demand for biologics. The government is actively supporting research and development through grants and tax incentives. Consumption patterns show a shift towards personalized medicine, reflecting changing patient needs and preferences.

### Argentina : Focus on Chronic Disease Management

Argentina accounts for a 3.5% share of the protein therapeutics market, valued at approximately $800 million. The market is driven by a growing aging population and an increase in chronic diseases such as diabetes and cancer. Regulatory bodies are enhancing their frameworks to support the introduction of new therapies. Local initiatives are also promoting partnerships between public and private sectors to boost research and development.

### Rest of South America : Varied Market Dynamics Across Regions

The Rest of South America holds a market share of 3.76%, valued at around $700 million. This sub-region showcases diverse market dynamics, with varying levels of healthcare access and regulatory environments. Countries like Chile and Colombia are emerging as key players, driven by government support for biotechnology. The competitive landscape includes both local and international firms, with a focus on addressing specific health challenges prevalent in these markets.

## Competitive Benchmarking

The protein therapeutics market in South America is characterized by a dynamic competitive landscape, driven by increasing demand for biologics and advancements in biotechnology. Key players such as Amgen (US), Genentech (US), and AbbVie (US) are strategically positioned to leverage innovation and regional expansion. Amgen (US) focuses on enhancing its biosimilar portfolio, while Genentech (US) emphasizes personalized medicine through targeted therapies. AbbVie (US) is actively pursuing mergers and acquisitions to bolster its pipeline, indicating a trend towards consolidation in the market. Collectively, these strategies contribute to a competitive environment that is increasingly focused on innovation and therapeutic efficacy.
In terms of business tactics, companies are localizing manufacturing to reduce costs and improve supply chain efficiency. The market structure appears moderately fragmented, with several players vying for market share. However, the influence of major companies is significant, as they set the pace for innovation and establish benchmarks for quality and efficacy in protein therapeutics. This competitive structure fosters an environment where smaller firms may struggle to compete unless they carve out niche markets or form strategic partnerships.
In October 2025, Roche (CH) announced a collaboration with a local biotech firm to develop a novel monoclonal antibody targeting autoimmune diseases. This partnership is strategically important as it allows Roche (CH) to tap into local expertise and accelerate the development of therapies tailored to the South American population. Such collaborations may enhance Roche's (CH) competitive edge by facilitating quicker market entry and addressing specific regional health needs.
In September 2025, Sanofi (FR) launched a new initiative aimed at increasing access to its protein therapeutics in underserved regions of South America. This initiative is significant as it not only expands Sanofi's (FR) market presence but also aligns with global health goals of improving healthcare access. By focusing on affordability and accessibility, Sanofi (FR) positions itself as a socially responsible leader in the market, potentially enhancing its brand reputation and customer loyalty.
In November 2025, Johnson & Johnson (US) unveiled a digital platform designed to streamline patient access to its protein therapeutics. This move reflects a broader trend towards digitalization in the healthcare sector, where technology plays a crucial role in enhancing patient engagement and adherence to treatment. By integrating digital solutions, Johnson & Johnson (US) is likely to improve patient outcomes and solidify its market position through enhanced service delivery.
As of November 2025, current trends in the protein therapeutics market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence in drug development. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition may redefine market dynamics, as companies that prioritize these aspects are likely to gain a competitive advantage.

## Recent News & Developments

The South America Protein Therapeutics Market is experiencing significant developments, particularly with leading companies such as Johnson and Johnson, Merck, Novartis, and Pfizer actively pursuing advancements in biologic therapies. Notably, in March 2023, Novartis announced a strategic partnership with a local biotech firm in Brazil aimed at accelerating the development of novel protein therapeutics targeting chronic diseases prevalent in the region. Additionally, Johnson and Johnson reinforced its commitment to the South American market by expanding its research facilities in Argentina, enhancing its capabilities in protein-based therapies.

In terms of market growth, Eli Lilly has reported impressive increases in its revenue from protein therapeutics, driven by strong demand for its diabetes treatments in Brazil and Argentina. The market valuation for protein therapeutics in South America is projected to reach approximately USD 15 billion by 2025, buoyed by an increase in healthcare spending and a growing prevalence of chronic diseases.

Furthermore, significant regulatory updates have been made in the region, streamlining approval processes for new protein-based therapies to enhance patient access and market entry for innovative treatments, reflecting a maturing landscape for biopharmaceuticals in South America over the past 2-3 years.

## Report Scope

| MARKET SIZE 2024 | 22.26(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 23.8(USD Billion) |
| MARKET SIZE 2035 | 46.47(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.92% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Amgen (US), Genentech (US), AbbVie (US), Bristol-Myers Squibb (US), Roche (CH), Sanofi (FR), Johnson & Johnson (US), Merck & Co. (US), Eli Lilly and Company (US) |
| Segments Covered | Type, Application, End Use, Mode of Administration |
| Key Market Opportunities | Emerging biomanufacturing technologies enhance efficiency in the protein therapeutics market. |
| Key Market Dynamics | Rising demand for innovative protein therapeutics drives competitive dynamics and regulatory adaptations in South America. |
| Countries Covered | Brazil, Mexico, Argentina, Rest of South America |

## Frequently Asked Questions

**Q: What was the market valuation of the protein therapeutics market in 2024?**
A: The market valuation was $22.26 Billion in 2024.

**Q: What is the projected market valuation for the protein therapeutics market by 2035?**
A: The projected valuation for 2035 is $46.47 Billion.

**Q: What is the expected CAGR for the protein therapeutics market during the forecast period 2025 - 2035?**
A: The expected CAGR is 6.92% during the forecast period 2025 - 2035.

**Q: Which segment had the highest valuation in 2024 within the protein therapeutics market?**
A: Monoclonal Antibodies had the highest valuation at $8.91 Billion in 2024.

**Q: What are the projected values for Recombinant Proteins by 2035?**
A: The projected value for Recombinant Proteins is $13.93 Billion by 2035.

**Q: Which application segment is expected to grow the most by 2035?**
A: Oncology is expected to grow the most, reaching $14.0 Billion by 2035.

**Q: What was the valuation of the Hospital end-use segment in 2024?**
A: The Hospital end-use segment was valued at $8.91 Billion in 2024.

**Q: What is the projected value for the Subcutaneous mode of administration by 2035?**
A: The projected value for the Subcutaneous mode of administration is $18.5 Billion by 2035.

**Q: Which key players are leading the protein therapeutics market?**
A: Key players include Amgen, Genentech, AbbVie, and Bristol-Myers Squibb.

**Q: What was the valuation of the Autoimmune Diseases application segment in 2024?**
A: The Autoimmune Diseases application segment was valued at $5.33 Billion in 2024.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-america-protein-therapeutics-market-51793*